Cargando…
Longitudinal profiling of the gut microbiome in patients with psoriatic arthritis and ankylosing spondylitis: a multicentre, prospective, observational study
BACKGROUND: Psoriasis is a chronic inflammatory disease of the skin affecting 2–3% of UK population. 30% of people affected by psoriasis will develop a distinct form of arthritis within 10 years of the skin condition onset. Although the pathogenesis of psoriatic arthritis is still unknown, there is...
Autores principales: | Miguens Blanco, Jesus, Borghese, Federica, McHugh, Neil, Kelleher, Peter, Sengupta, Raj, Marchesi, Julian R., Abraham, Sonya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653819/ https://www.ncbi.nlm.nih.gov/pubmed/33292821 http://dx.doi.org/10.1186/s41927-020-00155-2 |
Ejemplares similares
-
Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016) -
Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019) -
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020) -
Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis
por: Nielsen, Christel, et al.
Publicado: (2017) -
Association of Secukinumab Treatment With Tuberculosis Reactivation in
Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)